Odanacatib: the best osteoporosis treatment we never had?,The Lancet Diabetes & Endocrinology

当前位置： X-MOL 学术 › Lancet Diabetes Endocrinol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Odanacatib: the best osteoporosis treatment we never had?
The Lancet Diabetes & Endocrinology ( IF 44.0 ) Pub Date : 2019-10-31 , DOI: 10.1016/s2213-8587(19)30348-1
Louise A Statham ₁ , Terry J Aspray ₂

Affiliation

Current drugs used to treat osteoporosis target bone turnover. Oestrogens and oestrogen-receptor modulators in post-menopausal women, and bisphosphonates and denosumab in both sexes, all decrease bone resorption, and anabolic drugs such as teriparatide increase bone formation. However, the outcome of treatment with these drugs is affected by coupling of bone turnover; ie, decreased resorption also results in less bone formation and increased formation is associated with increased resorption. Odanacatib, a selective cathepsin-K inhibitor, can uncouple bone turnover so that bone resorption is reduced without substantially inhibiting bone formation. Additionally, a phase 2 study showed that odanacatib improved bone mineral density with no plateau in effect. In the Lancet Diabetes & Endocrinology, Michael McClung and colleagues present the results of their randomised placebo-controlled trial (LOFT) and extension study (LOFT Extension).

中文翻译：

Odanacatib：我们从未有过的最好的骨质疏松症治疗？

当前用于治疗骨质疏松症的药物靶向骨转换。绝经后妇女中的雌激素和雌激素受体调节剂，以及两性中的双膦酸盐和地诺单抗均会降低骨吸收，而合成代谢药物（如特立帕肽）则会增加骨形成。然而，用这些药物治疗的结果受骨转换耦合的影响。即减少的吸收也导致较少的骨形成，而增加的形成与增加的吸收有关。Odanacatib是一种选择性的组织蛋白酶K抑制剂，可以使骨骼更新解偶联，从而在不实质上抑制骨骼形成的情况下减少骨骼的吸收。此外，一项2期研究显示，奥达那替尼可改善骨矿物质密度，且无平台作用。在《柳叶刀》糖尿病和内分泌学中，Michael McClung及其同事介绍了他们的随机安慰剂对照试验（LOFT）和延伸研究（LOFT延伸）的结果。

更新日期：2019-11-20

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文